Autres langues Astellas Pharma Inc. OTC Markets

Actions

ALPMY

US04623U1025

Produits pharmaceutiques

Marché Fermé - OTC Markets Autres places de cotation 21:59:59 17/07/2026			Varia. 5j.	Varia. 1 janv.
13,28 ^USD	+0,53%		+0,68%	-0,08%

13/07	Pfizer et Astellas obtiennent le feu vert de la FDA pour leur traitement contre le cancer de la vessie	MT
10/07	Pfizer s'apprête à publier un deuxième trimestre mitigé, selon RBC	MT

Autres langues

13/07	Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug
10/07	Health Care Down on Rotation Back to Tech - Health Care Roundup
10/07	Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA
10/07	Pfizer Poised for Mixed Second Quarter, RBC Says
10/07	Pfizer Inc. and Astellas Pharma Inc. Receive U.S. FDA Approval for PADCEV Plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer
30/06	Trump's push for the world's lowest drug prices hits snag with mid-sized companies
26/06	Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets
24/06	Merck Wins European Commission Approval for KEYTRUDA Plus Padcev in Bladder Cancer
24/06	China detains two Japanese nationals suspected of smuggling banned goods
23/06	Eli Lilly, Astellas Enter Into Asset Sale Agreements With Sangamo Therapeutics
29/05	Astellas Pharma Inc. Announces Resignation of Andreas Busch, an Outside Director from His Position as Director Effective May 29, 2026
29/05	Astellas Pharma: Institutional Shareholder Services has issued a report recommending a vote against a director candidate
27/05	HEALTH ROUNDS-Veracyte genomic test identifies breast cancer patients who can skip chemo
26/05	Alert wrongly tagged to Gold Rain Enterprises withdrawn
18/05	Astellas Pharma Inc. Presents Data on Long-Term Outcomes and Clinical Use of its Oncology Portfolio at ASCO
12/05	Izervay® (avacincaptad pegol intravitreal solution) demonstrated increased probability of maintaining driving eligibility in geographic atrophy patients
27/04	Astellas Pharma's Profit Surges 475% in Fiscal 2025
27/04	Astellas Pharma Inc - Notice regarding impairment loss and extraordinary losses in non-consolidated financial results (J-GAAP)
27/04	Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2026
27/04	Astellas Pharma Inc. Announces Appointment Of Takahiko Iwaya As Chief Strategy Officer, Effective July 1, 2026
20/04	Merck Announces FDA Grants Priority Review For Keytruda And Keytruda Qlex Each With Padcev For Cisplatin-Eligible Patients With Muscle-Invasive Bladder Cancer
20/04	Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder Cancer
20/04	Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer
20/04	Merck Says FDA Grants Priority Review to Keytruda-Padcev Combo for Bladder Cancer
20/04	Sutro Biopharma Presents Promising Preclinical Data Across Its Pipeline of Next-Generation Single and Dual-Payload Adc Programs